Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$384M |
| 2 |
Mondelez International
MDLZ
|
+$125M |
| 3 |
NVIDIA
NVDA
|
+$116M |
| 4 |
Johnson & Johnson
JNJ
|
+$105M |
| 5 |
Church & Dwight Co
CHD
|
+$55.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$276M |
| 2 |
Apple
AAPL
|
+$180M |
| 3 |
Duke Energy
DUK
|
+$75.7M |
| 4 |
ConocoPhillips
COP
|
+$73.6M |
| 5 |
Broadcom
AVGO
|
+$70.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 11.11% |
| 2 | Technology | 9.83% |
| 3 | Utilities | 6.25% |
| 4 | Real Estate | 4.8% |
| 5 | Consumer Discretionary | 4.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1451
Riskified
RSKD
$783M
| $205K | ﹤0.01% |
+43,334
| New | +$237K |
|
1452
Kyverna Therapeutics
KYTX
$500M
| $205K | ﹤0.01% |
+41,984
| New | +$324K |
|
1453
Array Technologies
ARRY
$719M
| $203K | ﹤0.01% |
+30,813
| New | +$253K |
|
1454
VanEck JP Morgan EM Local Currency Bond ETF
EMLC
$4.84B
| $203K | ﹤0.01% |
8,000
| – | – |
|
|
NXDR
1455
Nextdoor Holdings
NXDR
$921M
| $201K | ﹤0.01% |
+80,935
| New | +$208K |
|
1456
Utz Brands
UTZ
$1.26B
| $195K | ﹤0.01% |
11,036
-89,309
| -89% | -$1.48M |
|
1457
Standard BioTools
LAB
$263M
| $194K | ﹤0.01% |
+100,309
| New | +$196K |
|
1458
SFL Corp
SFL
$1.65B
| $193K | ﹤0.01% |
16,695
-149,691
| -90% | -$1.79M |
|
1459
Voyager Therapeutics
VYGR
$201M
| $193K | ﹤0.01% |
+32,996
| New | +$240K |
|
1460
Kearny Financial
KRNY
$617M
| $190K | ﹤0.01% |
27,619
+8,684
| +46% | +$57.3K |
|
|
GRDN
1461
Guardian Pharmacy Services
GRDN
$2.42B
| $190K | ﹤0.01% |
+11,322
| New | +$191K |
|
1462
Nuvation Bio
NUVB
$2.36B
| $189K | ﹤0.01% |
+82,447
| New | +$251K |
|
1463
Mistras Group
MG
$604M
| $187K | ﹤0.01% |
+16,468
| New | +$169K |
|
|
CWEN.A
1464
DELISTED
Clearway Energy Class A
CWEN.A
| $183K | ﹤0.01% |
6,418
-732
| -10% | -$18.7K |
|
1465
PUT
Advanced Micro Devices
AMD
$745B
| $180K | ﹤0.01% |
1,100
-25,500
| -96% | -$3.87M |
|
1466
Boston Omaha
BOC
$426M
| $180K | ﹤0.01% |
12,133
-22,468
| -65% | -$313K |
|
1467
PUT
3M
MMM
$92.9B
| $178K | ﹤0.01% |
1,300
-31,600
| -96% | -$3.87M |
|
1468
Omeros
OMER
$1.35B
| $178K | ﹤0.01% |
+44,711
| New | +$191K |
|
1469
Akebia Therapeutics
AKBA
$247M
| $177K | ﹤0.01% |
+133,934
| New | +$179K |
|
|
ADVM
1470
DELISTED
Adverum Biotechnologies
ADVM
| $173K | ﹤0.01% |
+24,612
| New | +$179K |
|
1471
Old Second Bancorp
OSBC
$1.3B
| $173K | ﹤0.01% |
+11,065
| New | +$178K |
|
1472
CALL
PepsiCo
PEP
$198B
| $170K | ﹤0.01% |
1,000
-21,400
| -96% | -$3.68M |
|
|
VTYX
1473
DELISTED
Ventyx Biosciences
VTYX
| $166K | ﹤0.01% |
+76,007
| New | +$175K |
|
1474
Waldencast
WALD
$169M
| $166K | ﹤0.01% |
+45,613
| New | +$154K |
|
|
PTVE
1475
DELISTED
Pactiv Evergreen Inc. Common stock
PTVE
| $166K | ﹤0.01% |
+14,428
| New | +$166K |
|
Similar funds
Michael Gelband's Q3 2024 Portfolio in Review
As of Q3 2024, Michael Gelband held 2,213 positions worth $16.4B, up 12% from $14.7B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Michael Gelband deployed $963M of net new capital in Q3 2024, opening 752 new positions and adding to 404 existing holdings. Its largest new stake was Mondelez International: 1,784,906 shares worth $131M.
By sector, the portfolio is most concentrated in Healthcare at 11% of assets, up from 10% a quarter earlier, followed by Technology and Utilities.
On the sell side, the largest reduction was ConocoPhillips, an estimated $73.6M trimmed.
- Michael Gelband's largest Q3 2024 buy was Mondelez International: 1,784,906 shares worth $131M.
- Michael Gelband added most to Microsoft in Q3 2024, an estimated $384M increase.
- Michael Gelband's biggest Q3 2024 reduction was ConocoPhillips, cutting an estimated $73.6M.
- Michael Gelband fully exited Amazon in Q3 2024, selling an estimated $276M.
- Michael Gelband's ten largest holdings make up 37% of its $16.4B portfolio in Q3 2024.
- Michael Gelband opened 752 new positions and closed 645 in Q3 2024.
- Michael Gelband's portfolio value rose 12% quarter-over-quarter to $16.4B.
Based on ExodusPoint Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.